In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia, former president of the ACC, is joined by Dr C. Michael Gibson, CEO of the Baim Institute for Research, for an insightful discussion on the latest advancements and future directions in cardiovascular innovation for 2024.
Dr Itchhaporia and Dr Gibson explore strategies to enhance efficiency in cardiovascular research, with a focus on direct-to-patient trials. They delve into how this approach can be optimized to better target patients and improve outcomes. Dr. Gibson shares details about a groundbreaking platform being developed to support long-term follow-up studies, enabling patient monitoring for up to 20 years through persistent follow-up alerts.
The conversation also touches on key findings from the Apple Heart Study, particularly in relation to atrial fibrillation detection via the Apple Watch, and the differences in compliance rates between older and younger patients. Additionally, they discuss the upcoming results of the Heartline Study, which focuses on patients aged 65 and older.
Looking ahead, Dr Itchhaporia and Dr Gibson reflect on the future of cardiovascular care, including the potential for personalized care plans tailored to each patient. They consider the timeline for integrating this approach into clinical practice, potential barriers to implementation, and the significant opportunities it presents for improving patient outcomes.
If you have any questions or suggestions for topics to cover on the Radcliffe Podcast, please email managingeditor@ecrjournal.com.
Join renowned experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they preview the most impactful late-breaking studies poised to make waves at this year’s AHA Conference.
Supported by an unrestricted educational grant from NOVO NORDISK A/S.
Dr Irene Martin de Miguel (Hospital General Universitario Gregorio Marañón, Madrid, Spain) joins us in this featured author episode to outline her recent review article, Atrial Fibrillation in Congenital Heart Disease. In this podcast, Dr de Miguel provides an overview of the current knowledge of AF in CHD, giving practical recommendations for your everyday practice.
Today's episode features co-hosts Dr Peter Ong and Dr Andreas Seitz (Robert-Bosch Hospital, Stuttgart, DE) who together summarise the main results from the TARGET FFR and DEFINE-FLOW trials that were presented at TCT Connect 2020 and published recently in ECR journal, in the context of the existing literature.
Join interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) to learn more about this year’s key late-breaking and featured science trials that have the potential to shape practice and research.
They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.